Every day, scientists, companies and institutions work hard to help discover new treatment approaches and pathways – from activating the body’s own immune cells, to understanding how combination therapies could exponentially improve outcomes for cancer patients.

Cancer care is rapidly becoming more integrated and more specialised; whether their field is research, diagnosis, treatment, care, or advocacy, oncology professionals need to both build their specialist knowledge and connect with the best practitioners in other disciplines worldwide.

The Frontiers in Cancer Science (FCS) conference makes these objectives possible and serves as an excellent platform to converge the latest cancer discoveries around the world. The event is jointly organised by the Cancer Science Institute of Singapore, National University of Singapore (CSI Singapore), Duke-NUS Medical School, Genome Institute of Singapore (GIS), Institute of Molecular and Cell Biology (IMCB), Lee Kong Chian School of Medicine (LKCMedicine), National Cancer Centre Singapore (NCCS) and National University Cancer Institute, Singapore (NCIS).

Inaugurated in 2009 to seek insights about the ongoing and future prospect of cancer research worldwide, the event gathers some of the world's top cancer experts to share their latest advances and breakthroughs in the areas of cancer science, stem cell research and anti-cancer drug discoveries.

“Our main objectives and aspirations are to bring together leading cancer researchers from around the world to share recent advances, facilitate collaborations, and help Singapore cancer researchers build further international networks,” shared Professor David M. Virshup, FCS 2017 Organizing Committee Chair from Duke-NUS Medical School.

“The conference aims to accelerate the transfer of new knowledge between scientists at the benches, and the clinician scientists who are testing new therapies in patients. Oncologists and other healthcare professionals will have the opportunity to hear first-hand what exciting advances are being translated into new clinical therapies.”

Galvanising cancer research efforts

As one of only five institutions in Singapore awarded a $172 million “Research Centre of Excellence” grant by the government, CSI Singapore is dedicated to investigating the pathogenesis of cancer and creating innovative, safer methods of diagnosis and treatment. Established on 15 October 2008, over 200 scientists and researchers engage in life-saving work daily at the institute spearheaded by Professor Daniel G. Tenen, a world-leader in the field of transcriptional regulation, hematopoiesis and cancer.

The institution aims to deliver research leading to better cancer prevention, diagnosis and treatment, by recruiting outstanding talent and providing world-class training programs to nurture the next generation of research innovators. Home to world-renowned scientists and awardees of Singapore’s prestigious talent development program, the STaR Investigators, CSI Singapore endeavours to revolutionise the landscape of biomedical research and position Singapore as a global leader.

“The annual FCS conference has been instrumental in bringing the cancer research community together and helping CSI Singapore to share key achievements and future hopes for cancer research, supporting cross-pollination and joined-up research efforts for nine years running. I hope that the conference continues to deliver a powerful means of shaping the future of cancer research and drive forward progress. This year, I look forward to promote the exchange of new research and clinical developments and ideas in clinical oncology and cancer research,” highlighted Prof Tenen.

Key conference highlights

The three-day conference, which is now in its 9th year, will be held from 6th to 8th November 2017 at the Matrix Auditorium, Biopolis. An expected turnout of over 600 local and international delegates will have the opportunity to learn from 32 of the foremost local and international cancer experts as they share their newest findings and gain invaluable networking opportunities.

“Singapore has robust collaborations between busy doctors and distinguished academics. Meetings like FCS can make this even better by enhancing knowledge transfer, and we can’t underestimate the importance of face-to-face discussions between front line doctors, and laboratory based scientists,” Prof Virshup remarked.

Throughout the three-day event, discussions will revolve around methods and strategies related to management, quality improvement of cancer as well as to explore the new ideas and concepts on prevention, diagnosis and treatment of cancers and its innovative techniques.

FCS participants can look forward to a rewarding experience and gain useful insights through power-packed talks by prominent local and international speakers. The major discussion points will be based on the novel advancements in oncology, and will also include oral talks, poster presentations and exhibitions.

For more information on FCS 2017, please click here. MIMS